Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders

被引:35
作者
Chapoutot, Melinee [1 ,2 ]
Peter-Derex, Laure [1 ,2 ,3 ,4 ]
Bastuji, Helene [2 ,3 ,4 ]
Leslie, Wendy [5 ]
Schoendorff, Benjamin [6 ]
Heinzer, Raphael [7 ]
Siclari, Francesca [7 ]
Nicolas, Alain [2 ]
Lemoine, Patrick [1 ]
Higgins, Susan [8 ]
Bourgeois, Alexia [9 ]
Vallet, Guillaume T. T. [10 ]
Anders, Royce [11 ]
Ounnoughene, Marc [12 ]
Spencer, Jessica [13 ]
Meloni, Francesca [13 ]
Putois, Benjamin [1 ,2 ,13 ]
机构
[1] Assoc Natl Promot Connaissances Sommeil, F-69001 Lyon, France
[2] Lyon 1 Univ, CNRS UMR 5292, Lyon Neurosci Res Ctr, INSERM U1028, F-69005 Bron, France
[3] CHU Lyon, Croix Rousse Hosp, Sleep Med & Resp Dis Ctr, F-69004 Lyon, France
[4] Univ 1 Lyon, Fac Med Lyon Sud Charles Merieux, F-69622 Villeurbanne, France
[5] Xceltranslate, F-06000 Nice, France
[6] Inst Psychol Contextuelle, Montreal, PQ H2Y 2S9, Canada
[7] CHU Vaudois, Ctr Invest & Rech Sommeil, Lausanne, Switzerland
[8] Ctr Hosp Annecy Genevois, Serv Pneumol, F-74000 Annecy, France
[9] Univ Geneva, Lab Cognit Neurorehabilitat, Fac Med, CH-1201 Geneva, Switzerland
[10] Univ Clermont Auvergne, CNRS, LAPSCO, F-63000 Clermont Ferrand, France
[11] Lyon 2 Univ, Lab EMC, F-69500 Bron, France
[12] Cabinet Psychiatrie Plateau Haye, F-54320 Maxeville, France
[13] Swiss Distance Learning Univ, Fac Psychol, CH-3900 Brig, Switzerland
关键词
benzodiazepine; drug withdrawal; benzodiazepine taper; cognitive behavioral therapy; acceptance and commitment therapy; RANDOMIZED CONTROLLED-TRIAL; PROLONGED-RELEASE MELATONIN; OLDER-ADULTS; REBOUND INSOMNIA; DOUBLE-BLIND; ALPRAZOLAM DISCONTINUATION; PSYCHOLOGICAL TREATMENT; GRADUAL WITHDRAWAL; PATIENT EDUCATION; 3RD WAVE;
D O I
10.3390/ijerph181910222
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Benzodiazepines have proven to be highly effective for treating insomnia and anxiety. Although considered safe when taken for a short period of time, a major risk-benefit dilemma arises in the context of long-term use, relating to addiction, withdrawal symptoms, and potential side effects. For these reasons, benzodiazepines are not recommended for treating chronic sleep disorders, anxiety disorders, nor for people over the age of 65, and withdrawal among long-term users is a public health issue. Indeed, only 5% of patients manage to discontinue using these drugs on their own. Even with the help of a general practitioner, this rate does not exceed 25 to 30% of patients, of which approximately 7% manage to remain drug-free in the long term. Cognitive Behavioral Therapies (CBT) offer a crucial solution to this problem, having been shown to increase abstinence success to 70-80%. This article examines traditional and novel CBT techniques in this regard, such as Acceptance and Commitment Therapy, which address both the underlying condition (insomnia/anxiety) and the substance-related disorder. The theoretical framework and evidence supporting the use of these approaches are reviewed. Finally, current research gaps are discussed, and key research perspectives are proposed.
引用
收藏
页数:19
相关论文
共 147 条
[1]  
Agence Nationale de Securite du Medicament et Des Produits de Sante, 2017, ET LIE CONS BENZ
[2]   Psychological predictors of benzodiazepine discontinuation among older adults: Results from the PASSE 60+ [J].
Allary, Arnaud ;
Proulx-Tremblay, Virginie ;
Belanger, Claude ;
Hudon, Carol ;
Marchand, Andre ;
O'Connor, Kieron ;
Perodeau, Guilheme ;
Roberge, Pasquale ;
Tannenbaum, Cara ;
Vasiliadis, Helen-Maria ;
Desrosiers, Caroline ;
Cruz-Santiago, Diana ;
Grenier, Sebastien .
ADDICTIVE BEHAVIORS, 2020, 102
[3]   Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial [J].
Baandrup, Lone ;
Lindschou, Jane ;
Winkel, Per ;
Gluud, Christian ;
Glenthoj, Birte Y. .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2016, 17 (07) :514-524
[4]   Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013 [J].
Bachhuber, Marcus A. ;
Hennessy, Sean ;
Cunningham, Chinazo O. ;
Starrels, Joanna L. .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2016, 106 (04) :686-688
[5]  
Baillargeon L, 2003, CAN MED ASSOC J, V169, P1015
[6]   Benzodiazepines: Risks and benefits. A reconsideration [J].
Baldwin, David S. ;
Aitchison, Katherine ;
Bateson, Alan ;
Curran, H. Valerie ;
Davies, Simon ;
Leonard, Brian ;
Nutt, David J. ;
Stephens, David N. ;
Wilson, Sue .
JOURNAL OF PSYCHOPHARMACOLOGY, 2013, 27 (11) :967-971
[7]   Efficacy of treatments for anxiety disorders: a meta-analysis [J].
Bandelow, Borwin ;
Reitt, Markus ;
Roever, Christian ;
Michaelis, Sophie ;
Goerlich, Yvonne ;
Wedekind, Dirk .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (04) :183-192
[8]  
Barlow D.H., 1989, Mastery of your anxiety and panic
[9]   BEHAVIORAL TREATMENT OF PANIC DISORDER [J].
BARLOW, DH ;
CRASKE, MG ;
CERNY, JA ;
KLOSKO, JS .
BEHAVIOR THERAPY, 1989, 20 (02) :261-282
[10]  
BASHIR K, 1994, BRIT J GEN PRACT, V44, P408